OBJECTIVE: To review current evidence of pharmacological options for managing @entity4806 and provide potential areas for future research. DATA SOURCES: A MEDLINE search (1966 to October 2014) was conducted using the following keywords: exenatide, liraglutide, @entity24172 , @entity2449 , @entity28 , @entity350 , pediatric, @entity21938 , @entity12530 , @entity1771 , @entity353 , and @entity10315 . STUDY SELECTION AND DATA EXTRACTION: Identified articles were evaluated for inclusion, with priority given to randomized controlled trials with @entity350 , @entity2449 , @entity5445 agonists, @entity1771 , and @entity10315 in @entity1 subjects and articles written in English. References were also reviewed for additional trials. DATA SYNTHESIS: Whereas lifestyle modification is considered first-line therapy for @entity28 pediatric @entity1 , severe @entity28 may benefit from pharmacotherapy. @entity350 is the only Food and Drug Administration (FDA)-approved medication for @entity4806 and reduced body mass index (BMI) by 0.5 to 4 kg/m(2), but gastrointestinal (GI) adverse effects may limit use. @entity2449 has demonstrated BMI reductions of 0.17 to 1.8 kg/m(2), with mild GI adverse effects usually managed with dose titration. Exenatide reduced BMI by 1.1 to 1.7 kg/m(2) and was well-tolerated with mostly transient or mild GI adverse effects. @entity1771 and @entity10315 reduced weight when used in the treatment of @entity302 . Future studies should examine efficacy and safety of pharmacological agents in addition to lifestyle modifications for @entity4806 . CONCLUSIONS: Lifestyle interventions remain the treatment of choice in @entity4806 , but concomitant pharmacotherapy may be beneficial in some @entity1 . @entity350 should be considered as second-line therapy for @entity4806 . Evidence suggests that other @entity6 and antiepileptic medications may also provide weight-loss benefits, but safety should be further evaluated.

Pharmacological Management of Obesity in Pediatric XXXX .

@entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity350 :: ('MESH:C055122', 'Chemical') :: ['Orlistat', 'orlistat'] @entity12530 :: ('MESH:C105254', 'Chemical') :: ['pramlintide'] @entity24172 :: ('MESH:C506658', 'Chemical') :: ['lorcaserin'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obese', 'obesity'] @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity4806 :: ('MESH:D063766', 'Disease') :: ['pediatric obesity'] @entity21938 :: ('MESH:D010645', 'Chemical') :: ['phentermine'] @entity10315 :: ('MESH:C022189', 'Chemical') :: ['zonisamide'] @entity1771 :: ('MESH:C052342', 'Chemical') :: ['Topiramate', 'topiramate'] @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy'] @entity5445 :: ('2641', 'Gene') :: ['glucagon-like peptide-1'] @entity2449 :: ('MESH:D008687', 'Chemical') :: ['Metformin', 'metformin']
@entity1 :: (9606,Species) :: ['Patients']
